Merck's hep C combo hits cure-rate goal in IV drug users; Meda's Elidel could suffer on Valeant pharmacy snafu;

> Merck & Co.'s ($MRK) forthcoming hepatitis C regimen got a boost from new data showing that it delivered a high cure rate in patients who use intravenous drugs, the "hot core" of people with the disease. Report

> Sweden's Meda, whose dermatology drug Elidel is licensed in the U.S. to Valeant Pharmaceuticals ($VRX), could see sales disruptions from its partner's specialty pharmacy woes. Report

> Gilead Sciences ($GILD) won expanded FDA approval for its blockbuster hepatitis C combo pill Harvoni, extending use to new subtypes of hep C and to patients co-infected with HIV. Report

And Finally... Professional cycling's Team Novo Nordisk met with Pope Francis for World Diabetes Day last week. Report

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.